A detailed history of Vanguard Group Inc transactions in Deciphera Pharmaceuticals, Inc. stock. As of the latest transaction made, Vanguard Group Inc holds 4,565,044 shares of DCPH stock, worth $0. This represents 0.0% of its overall portfolio holdings.

Number of Shares
4,565,044
Previous 4,401,636 3.71%
Holding current value
$0
Previous $71 Million 1.14%
% of portfolio
0.0%
Previous 0.0%

Shares

12 transactions
Quarter Operation Price Per share shares change shares Held SEC Form
Q1 2024

May 10, 2024

BUY
$13.58 - $17.36 $2.22 Million - $2.84 Million
163,408 Added 3.71%
4,565,044 $71.8 Million
Q4 2023

Feb 14, 2024

BUY
$10.11 - $16.54 $335,682 - $549,177
33,203 Added 0.76%
4,401,636 $71 Million
Q3 2023

Nov 14, 2023

SELL
$12.46 - $15.48 $297,009 - $368,996
-23,837 Reduced 0.54%
4,368,433 $55.6 Million
Q2 2023

Aug 14, 2023

SELL
$13.28 - $15.96 $2.91 Million - $3.49 Million
-218,820 Reduced 4.75%
4,392,270 $61.8 Million
Q1 2023

May 15, 2023

SELL
$14.26 - $22.1 $1.91 Million - $2.97 Million
-134,231 Reduced 2.83%
4,611,090 $71.2 Million
Q4 2022

Feb 10, 2023

SELL
$14.85 - $19.04 $737,629 - $945,754
-49,672 Reduced 1.04%
4,745,321 $77.8 Million
Q3 2022

Nov 14, 2022

BUY
$12.38 - $20.23 $4.98 Million - $8.13 Million
402,047 Added 9.15%
4,794,993 $88.7 Million
Q2 2022

Aug 12, 2022

BUY
$9.11 - $13.98 $7.27 Million - $11.2 Million
798,434 Added 22.21%
4,392,946 $57.8 Million
Q1 2022

May 13, 2022

BUY
$6.87 - $11.11 $860,089 - $1.39 Million
125,195 Added 3.61%
3,594,512 $33.3 Million
Q4 2021

Feb 14, 2022

SELL
$7.7 - $37.13 $3.6 Million - $17.3 Million
-467,068 Reduced 11.87%
3,469,317 $33.9 Million
Q3 2021

Nov 12, 2021

BUY
$26.46 - $37.15 $229,699 - $322,499
8,681 Added 0.22%
3,936,385 $134 Million
Q2 2021

Aug 13, 2021

BUY
$32.73 - $47.95 $129 Million - $188 Million
3,927,704 New
3,927,704 $144 Million

Others Institutions Holding DCPH

About Deciphera Pharmaceuticals, Inc.


  • Ticker DCPH
  • Exchange NASDAQ
  • Sector Healthcare
  • Industry Drug Manufacturers—Specialty & Generic
  • Shares Outstandng 66,822,100
  • Description
  • Deciphera Pharmaceuticals, Inc., a biopharmaceutical company, develops drugs to enhance the lives of cancer patients by addressing key mechanisms of drug resistance that limit the rate and durability of response to existing cancer therapies in the United States and internationally. Its lead drug candidate is QINLOCK used for the treatment of gas...
More about DCPH
Track This Portfolio

Track Vanguard Group Inc Portfolio

Follow Vanguard Group Inc and customize your updates to receive the information that matters most to you.

Portfolio Update

Get notified when there are updates to the investment portfolio of Vanguard Group Inc, based on Form 13F filings with the SEC.

News

Stay updated on Vanguard Group Inc with notifications on news.